Will innate bispecifics make a difference in hematologic malignancies and solid tumours?
After yesterday’s look at a biotech company (F-star) who are focused on adaptive approaches with bispecific antibodies using checkpoint and immune agonist targets, we now shift direction within Europe to a completely different concept, although both are tetramer-based.
Oncology R&D can be a stop-start journey that is highly unpredictable and uncertain!
In the third part of our latest mini-series on bispecific antibodies, we now take a look a company who are evaluating this modality as a way to activate NK cells and stimulate the innate immune system. With all the fuss and attention on the adaptive immune system and checkpoint blockade, is there a role for innate immunotherapies?
Rather than look at this aspect as competitive, smart companies are seeking ways to complement existing backbones to determine if the outcomes can be boosted by targeting both innate and adaptive systems in a more coordinated manner.
To find out more about these developments, we talked to Dr Adi Hoess, CEO of Affimed, a German biotech company who are developing innate immunotherapies.
They have certainly been on a roller coaster ride of late, with clinical hold and abandonment of a leading program balanced by encouraging initial data with other projects, so what gives?
To learn more and get a heads up on our latest oncology insights and thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
